Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease

Utibe R. Essien; Karen E. Joynt Maddox; Stacie B. Dusetzina

doi:10.1161/circulationaha.126.080521

Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease

U Utibe R. Essien (Division of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA (U.R.E.).) K Karen E. Joynt Maddox S Stacie B. Dusetzina

View Original

APA MLA Chicago BibTeX RIS

Article Details

Journal Circulation

Volume / Issue Vol. 153, Issue 24

Published June 16, 2026

Pages 1884-1886

DOI 10.1161/circulationaha.126.080521

ISSN 0009-7322

Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (3)

U

Utibe R. Essien

Division of General Internal Medicine & Health Services Research, David Geffen School of Medicine at UCLA, Los Angeles, CA (U.R.E.).

K

Karen E. Joynt Maddox

S

Stacie B. Dusetzina

Pharmacoequity and the Promise of GLP-1 Therapies in Cardiovascular Disease

Article Details

Journal Info

Authors (3)

Related Articles from this Journal

Occupational Radiation Safety in Electrophysiology During Pregnancy: Evaluating Uterine Radiation Doses During Catheter Ablations and Device Implantations

Response by Rogers et al to Letter Regarding, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”

Clinical Cardiology at the Crossroads: Perspectives on the Next Era at <i>Circulation</i>

ABHD11-Mediated mtDNA Transcription Restored Mitochondrial Function to Attenuate Cardiomyocyte Ferroptosis After Myocardial Infarction

Letter by Li et al Regarding Article, “Deep Learning-Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation”